Allogene Therapeutics
ALLO
169 hedge funds and large institutions have $3.12B invested in Allogene Therapeutics in 2021 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 44 increasing their positions, 63 reducing their positions, and 29 closing their positions.
264% more call options, than puts
Call options by funds: $16.5M | Put options by funds: $4.53M
38% more capital invested
Capital invested by funds: $2.26B → $3.12B (+$860M)
17% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 29
2% more funds holding
Funds holding: 165 → 169 (+4)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.98% less ownership
Funds ownership: 63.81% → 62.83% (-0.98%)
30% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$19.9M |
| 2 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$18.1M |
| 3 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
+$18.1M |
| 4 |
HM
HealthCor Management
New York
|
+$16.7M |
| 5 |
JP Morgan Chase
New York
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$35.1M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$17.8M |
| 3 |
SCM
Suvretta Capital Management
New York
|
-$12.2M |
| 4 |
CII
Capital International Inc
Los Angeles,
California
|
-$11.3M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$9.46M |
ALLO Hedge Fund Activity: Q1 2021 in Review
169 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q1 2021, worth a combined $3.12B — up 38% from $2.26B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ALLO positions and 29 closed out — a net gain of 5 holders — while 44 added to existing stakes and 63 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $19.9M. The largest seller was State Street, cutting an estimated $35.1M.
- 169 institutional investors held Allogene Therapeutics (ALLO) as of Q1 2021, up from 165 in Q4 2020.
- Funds reported $3.12B of Allogene Therapeutics stock for Q1 2021, up 38% quarter-over-quarter.
- 34 funds opened new Allogene Therapeutics positions in Q1 2021 and 29 closed out, a net change of +5 holders.
- The largest Allogene Therapeutics buyer in Q1 2021 was PFM Health Sciences, an estimated $19.9M added.
- The largest Allogene Therapeutics seller in Q1 2021 was State Street, an estimated $35.1M sold.
Based on aggregated 13F filings for Q1 2021.